Younong Yu

发表

Diaminocyclobutenediones as potent and orally bioavailable CXCR2 receptor antagonists: SAR in the phenolic amide region.

M. Dwyer, D. Rindgen, D. Lundell, 2009, Bioorganic & medicinal chemistry letters.

Fluoroalkyl alpha side chain containing 3,4-diamino-cyclobutenediones as potent and orally bioavailable CXCR2-CXCR1 dual antagonists.

M. Dwyer, D. Rindgen, D. Lundell, 2009, Bioorganic & medicinal chemistry letters.

3,4-Diamino-1,2,5-thiadiazole as potent and selective CXCR2 antagonists.

Junying Zheng, J. Fossetta, D. Lundell, 2009, Bioorganic & medicinal chemistry letters.

Synthesis and structure-activity relationships of heteroaryl substituted-3,4-diamino-3-cyclobut-3-ene-1,2-dione CXCR2/CXCR1 receptor antagonists.

M. Dwyer, D. Rindgen, J. Fossetta, 2008, Bioorganic & medicinal chemistry letters.

3,4-Diamino-2,5-thiadiazole-1-oxides as potent CXCR2/CXCR1 antagonists.

Junying Zheng, J. Baldwin, D. Rindgen, 2008, Bioorganic & medicinal chemistry letters.

C(4)-alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists.

M. Dwyer, D. Rindgen, D. Lundell, 2007, Bioorganic & medicinal chemistry letters.

Discovery of 3-morpholino-imidazole[1,5-a]pyrazine BTK inhibitors for rheumatoid arthritis.

T. Fischmann, K. Maloney, C. Garlisi, 2017, Bioorganic & medicinal chemistry letters.

A new synthesis of 3,4-disubstituted 1,2,5-thiadiazoles

Younong Yu, P. Biju, 2007 .

Discovery of Highly Selective and Potent HDAC3 Inhibitors Based on a 2-Substituted Benzamide Zinc Binding Group.

D. Klein, M. Holloway, B. Howell, 2020, ACS medicinal chemistry letters.

Discovery of ethyl ketone-based HDACs 1, 2, and 3 selective inhibitors for HIV latency reactivation.

James I. Fells, D. Klein, R. Myers, 2020, Bioorganic & medicinal chemistry letters.

Synthesis of HDAC Inhibitor Libraries via Microscale Workflow.

R. Myers, P. Váchal, M. Maletic, 2021, ACS medicinal chemistry letters.

Selective Class I HDAC Inhibitors Based on Aryl Ketone Zinc Binding Induce HIV-1 Protein for Clearance.

James I. Fells, Joseph James Duffy, D. Klein, 2020, ACS medicinal chemistry letters.

Discovery of novel BTK inhibitors with carboxylic acids.

T. Fischmann, K. Maloney, C. Garlisi, 2017, Bioorganic & medicinal chemistry letters.

Substituted dibenzo[c,h]cinnolines: topoisomerase I-targeting anticancer agents.

E. LaVoie, Leroy F. Liu, Tsai-Kun Li, 2003, Bioorganic & medicinal chemistry.

Synthesis of the oxygenated pactamycin core.

S. Knapp, Younong Yu, 2007, Organic letters.

Discovery of 8-Amino-imidazo[1,5-a]pyrazines as Reversible BTK Inhibitors for the Treatment of Rheumatoid Arthritis.

V. Hornak, T. Fischmann, K. Maloney, 2016, ACS medicinal chemistry letters.

Chemoselective Peptide Modification via Photocatalytic Tryptophan β-Position Conjugation.

Li-Kang Zhang, Alexei V Buevich, P. Váchal, 2018, Journal of the American Chemical Society.

CXCR2 modulators: a patent review (2009 – 2013)

M. Dwyer, Younong Yu, 2014, Expert opinion on therapeutic patents.

Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist.

M. Dwyer, J. Baldwin, L. Ozgur, 2006, Journal of medicinal chemistry.

Potent, non-covalent reversible BTK inhibitors with 8-amino-imidazo[1,5-a]pyrazine core featuring 3-position bicyclic ring substitutes.

T. Fischmann, K. Maloney, C. Garlisi, 2020, Bioorganic & medicinal chemistry letters.

CXCR2 receptor antagonists: a medicinal chemistry perspective.

M. Dwyer, Younong Yu, 2014, Current topics in medicinal chemistry.

Quality by design (QbD) of amide isosteres: 5,5-Disubstituted isoxazolines as potent CRTh2 antagonists with favorable pharmacokinetic and drug-like properties.

Xiaohong Zhu, A. Palani, Jie Wu, 2014, Bioorganic & medicinal chemistry letters.

Chemoselective Peptide Modification via Photocatalytic Tryptophan β-Position Conjugation.

Li-Kang Zhang, S. Colletti, Haiqun Tang, 2018, Journal of the American Chemical Society.

Use of molecular modeling aided design to dial out hERG liability in adenosine A(2A) receptor antagonists.

Yeon-Hee Lim, Junying Zheng, A. Stamford, 2015, Bioorganic & medicinal chemistry letters.